Haloallylamine sulfone derivative inhibitors of lysyl oxidases and uses thereof

A Z-isomer compound of Formula I:

• or a pharmaceutically acceptable salt, polymorphic form, solvate, hydrate or tautomeric form thereof;
• wherein:
• A is selected from the group consisting of:
• each R1 is independently selected from the group consisting of X—R2, halogen, deuterium, C1-6alkyl, O—C1-6alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —CN, —C(O) OR3, —C(O) NR4R5, —S(O)2NR4R5, —S(O)2R6, —NR8C(O)R9, and —NR8S(O)2R9;
• wherein each C1-6alkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SO2CH3, —C1-4alkyl, —O—C1-4alkyl, —CF3, —CH2CF3 and —O—CF3;
• X is selected from the group consisting of O, CH2, OCH2, CH2O, CH2S(O)2, CONH and NHCO;
• R2 is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl;
• wherein each R2 is optionally substituted by one or more R7;
• R3 is selected from the group consisting of hydrogen, C1-6alkyl and C3-7cycloalkyl;
• wherein each C1-6alkyl and C3-7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SO2CH3, —C1-4alkyl, —O—C1-4alkyl, —CF3, —CH2CF3 and —O—CF3;
• R4 and R5 are independently selected from the group consisting of hydrogen, C1-6alkyl and C3-7cycloalkyl;
• wherein each C1-6alkyl and C3-7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —SO2CH3, —C1-4alkyl, —O—C1-4alkyl, —CF3, —CH2CF3 and —O—CF3;
• or
• R4 and R5 when attached to the same nitrogen atom are combined to form a 4- to 7-membered ring having from 0 to 1 additional heteroatoms as ring members;
• R6 is selected from the group consisting of C1-6alkyl and C3-7cycloalkyl;
• wherein each C1-6alkyl and C3-7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C1-4alkyl, —O—C1-4alkyl, —CF3, —CH2CF3, and —O—CF3;
• R7 is selected from the group consisting of halogen, —OH, C1-6alkyl, O—C1-6alkyl C3-7cycloalkyl, —C(O) OR3, —C(O) NR4R5, —NR4C(O)R6, —S(O)2NR4R5, —NR4S(O)2R6 and —S(O)2R6;
• wherein each C1-6alkyl is optionally substituted by one or more substituents selected from the group consisting of halogen and —OH;
• R8 is hydrogen or C1-6alkyl;
• R9 is selected from the group consisting of C1-6alkyl and C3-7cycloalkyl;
• wherein each C1-6alkyl and C3-7cycloalkyl is optionally substituted by one or more substituents selected from the group consisting of halogen, —OH, —C1-4alkyl, —O—C1-4alkyl, —CF3, —CH2CF3, and —O—CF3;
• or
• R8 and R9 are combined to form a 5- to 7-membered ring having from 0 to 1 additional heteroatoms as ring members;
• and
• n is 0, 1, 2, 3, 4, 5 or 6.